Skip to main content

Natco braces for major patent battle in US, submits ANDA of cancer drug Imbruvica

Natco braces for major patent battle in US, submits ANDA of cancer drug Imbruvica As per the USFDA#39;s Orange Book contains that data of all approved drugs in US, the patents of Imbruvica will start expiry only from 2026, some patents are valid all the way till 2033-2034.

from Moneycontrol Business News http://bit.ly/2ToZSur

Comments

Popular posts from this blog

German cabinet to hold secret session on Huawei#39;s role in 5G network: Report

Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology for spying, which the company denies. from Moneycontrol Business News http://bit.ly/2TyXzFb

Infosys partners Avaloq to strengthen wealth management capabilities via digital platforms

Infosys will be a strategic implementation partner for Avaloq#39;s wealth management suite of solutions to help clients modernize and transform their legacy systems into cutting-edge digital advisory platforms, a statement said. from Moneycontrol Business News https://ift.tt/2THaSpn